This article is written by William Fuller, Director of Business Development, DSM Biomedical.

Innovation and constant advancement dominate the medical device industry due to the changing healthcare landscape and patient demand for high quality outcomes. Many of the advances in the medical device industry will come from revolutionary biomaterials that help enable the function of the devices. The impact of these novel biomaterials will be particularly significant to orthopedic implant devices.

DSM, a biomedical materials developer, has entered into a license and supply agreement with SpineVision, an implant manufacturer.

Royal DSM, a global life sciences and materials sciences company, has acquired biomedical company Kensey Nash for $360 million.

DSM, a global science-based company active in health, nutrition and materials, and AdeTherapeutics, a clinical-stage product development company located in Canada, signed a joint collaboration agreement to accelerate DSM's scar reduction and pain management product development strategy in neurosurgery, according to a news release.